Medicinal chemistry of cannabinoids

The endocannabinoid system comprises the two well characterized Gi/o‐protein coupled receptors (cannabinoid receptor 1 (CB1) and CB2), their endogenous lipid ligands, and the enzymes involved in their biosynthesis and biotransformation. Drug discovery efforts relating to the endocannabinoid system h...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2015-06, Vol.97 (6), p.553-558
Hauptverfasser:	Vemuri, V Kiran, Makriyannis, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Amidohydrolases - antagonists & inhibitors Cannabinoids - therapeutic use Chemistry, Pharmaceutical Drug Discovery Humans Monoacylglycerol Lipases - antagonists & inhibitors Receptor, Cannabinoid, CB1 - agonists Receptor, Cannabinoid, CB1 - antagonists & inhibitors Receptor, Cannabinoid, CB1 - physiology Receptor, Cannabinoid, CB2 - agonists Receptor, Cannabinoid, CB2 - physiology Translation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The endocannabinoid system comprises the two well characterized Gi/o‐protein coupled receptors (cannabinoid receptor 1 (CB1) and CB2), their endogenous lipid ligands, and the enzymes involved in their biosynthesis and biotransformation. Drug discovery efforts relating to the endocannabinoid system have been focused mainly on the two cannabinoid receptors and the two endocannabinoid deactivating enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). This review provides an overview of cannabinergic agents used in drug research and those being explored clinically.
ISSN:	0009-9236 1532-6535
DOI:	10.1002/cpt.115